An article by Jared Kaltwasser, in Managed Healthcare executive in its latest issue, sheds light on the growing restrictions imposed by commercial insurers on treatments for pulmonary arterial hypertension. An examination of 17 major insurance plans from 2017 to 2022 showed a sharp increase in policies with at least one restriction, jumping from 38% to 73%. Additionally, there was a notable rise in “step therapy” requirements, which mandates patients to try less expensive drugs before moving to pricier options. This inconsistency among insurers results in unequal access to treatments and complicates matters further for prescribers due to frequent policy changes.
For more details, you can read the full article at this link.
share this: